CL2018003210A1 - Selección directa de células que expresan niveles altos de proteínas heterodiméricas usando vectores de complementación intragénica de glutamina sintetasa. - Google Patents

Selección directa de células que expresan niveles altos de proteínas heterodiméricas usando vectores de complementación intragénica de glutamina sintetasa.

Info

Publication number
CL2018003210A1
CL2018003210A1 CL2018003210A CL2018003210A CL2018003210A1 CL 2018003210 A1 CL2018003210 A1 CL 2018003210A1 CL 2018003210 A CL2018003210 A CL 2018003210A CL 2018003210 A CL2018003210 A CL 2018003210A CL 2018003210 A1 CL2018003210 A1 CL 2018003210A1
Authority
CL
Chile
Prior art keywords
intragenic
supplementation
vectors
cells expressing
high levels
Prior art date
Application number
CL2018003210A
Other languages
English (en)
Inventor
Randal R Ketchem
Neeraj Jagdish Agrawal
Jeffrey T Mcgrew
Yadlin Dina A Fomina
Trent P Munro
Kristine M Daris
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2018003210A1 publication Critical patent/CL2018003210A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/01—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with NAD+ or NADP+ as acceptor (1.4.1)
    • C12Y104/01002—Glutamate dehydrogenase (1.4.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/04—Other carbon-nitrogen ligases (6.3.4)
    • C12Y603/04004—Adenylosuccinate synthase (6.3.4.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/04—Other carbon-nitrogen ligases (6.3.4)
    • C12Y603/04005—Argininosuccinate synthase (6.3.4.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

ESTA INVENCIÓN SE REFIERE AL CAMPO GENERAL DE LA EXPRESIÓN RECOMBINANTE DE POLIPÉPTIDOS EN CULTIVOS CELULARES DE ANIMALES. MÁS ESPECÍFICAMENTE, LA INVENCIÓN SE REFIERE A LA SELECCIÓN DE CÉLULAS TRANSFECTADAS CON VECTORES MODIFICADOS GENÉTICAMENTE DE MANERA RECOMBINANTE DISEÑADOS PARA EXPRESAR POLIPÉPTIDOS, EN POLIPÉPTIDOS HETERODIMÉRICOS PARTICULARES.
CL2018003210A 2016-05-11 2018-11-12 Selección directa de células que expresan niveles altos de proteínas heterodiméricas usando vectores de complementación intragénica de glutamina sintetasa. CL2018003210A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662334966P 2016-05-11 2016-05-11

Publications (1)

Publication Number Publication Date
CL2018003210A1 true CL2018003210A1 (es) 2019-02-15

Family

ID=58873869

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003210A CL2018003210A1 (es) 2016-05-11 2018-11-12 Selección directa de células que expresan niveles altos de proteínas heterodiméricas usando vectores de complementación intragénica de glutamina sintetasa.

Country Status (17)

Country Link
US (2) US11384140B2 (es)
EP (2) EP4067493A1 (es)
JP (2) JP6972022B2 (es)
KR (2) KR102439719B1 (es)
CN (2) CN109219660B (es)
AU (2) AU2017263454B2 (es)
BR (1) BR112018073316A2 (es)
CA (1) CA3024027A1 (es)
CL (1) CL2018003210A1 (es)
EA (1) EA201892588A1 (es)
ES (1) ES2914118T3 (es)
IL (2) IL300591A (es)
MA (1) MA44976A (es)
MX (2) MX2018013882A (es)
SG (1) SG11201810040WA (es)
TW (2) TWI757291B (es)
WO (1) WO2017197098A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190352631A1 (en) * 2016-11-16 2019-11-21 Agency For Science Technology And Research Attenuated Glutamine Synthetase as a Selection Marker
CA3064352A1 (en) 2017-05-24 2018-11-29 Thoeris Gmbh Use of glutamine synthetase for treating hyperammonemia
CN109988777A (zh) * 2017-12-29 2019-07-09 南京金斯瑞生物科技有限公司 谷氨酰胺合成酶基因以及应用
WO2020227206A1 (en) * 2019-05-07 2020-11-12 Amgen Inc. Vectors and expression systems for producing recombinant proteins
WO2023011442A1 (en) * 2021-08-03 2023-02-09 Shanghai Zhenge Biotechnology Co., Ltd. Selectable markers for eukaryotic expression system
WO2023180398A1 (en) 2022-03-23 2023-09-28 Boehringer Ingelheim International Gmbh Bacterial glutamine synthetase as selection marker in mammalian cells
WO2023180374A1 (en) 2022-03-23 2023-09-28 Boehringer Ingelheim International Gmbh New glutamine synthetase variants as selection marker
CN118006685A (zh) * 2024-04-07 2024-05-10 上海碧博生物医药科技有限公司 一种快速的高表达单克隆细胞株构建方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPH0819508B2 (ja) 1987-08-19 1996-02-28 三菱マテリアル株式会社 Ｆｅ−Ｃｏ基合金製高周波用磁芯材
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5624818A (en) 1991-09-09 1997-04-29 Fred Hutchinson Cancer Research Center Nucleic acids encoding regulatory proteins that dimerize with Mad or Max
EP0897983B1 (en) 1991-10-25 2003-05-07 Immunex Corporation Antibody against CD40-L
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5573925A (en) 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains
NZ311335A (en) 1995-06-07 1998-05-27 Immunex Corp Cd40l muteins and their use as ligands
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
DK1196566T3 (da) * 1999-07-12 2006-06-06 Genentech Inc Ekspressionsvektorer og -metoder
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
EP3467117B1 (en) * 2001-09-20 2020-07-15 Immunex Corporation Selection of cells expressing heteromeric polypeptides
GB0200977D0 (en) * 2002-01-17 2002-03-06 Lonza Biologics Plc Glutamine-auxotrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium
AU2003298606A1 (en) * 2002-10-25 2004-05-13 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
US7384744B2 (en) * 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
ES2374526T3 (es) * 2003-09-04 2012-02-17 Medarex, Inc. Vector de expresión.
ES2629397T3 (es) 2004-09-24 2017-08-09 Amgen Inc. Moléculas de Fc modificadas
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070254338A1 (en) * 2006-04-24 2007-11-01 Amgen Inc. Method for making recombinant protein using complementation dependent DHFR mutants
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
WO2012027533A1 (en) * 2010-08-25 2012-03-01 Gt Life Sciences, Inc. Selectable markers and related methods
US20130244231A1 (en) * 2010-11-08 2013-09-19 Jcr Pharmaceuticals Co., Ltd. Novel expression vector
WO2012095514A1 (en) * 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
US8809017B2 (en) * 2011-05-24 2014-08-19 Agency For Science, Technology And Research IRES mediated multicistronic vectors
KR101411740B1 (ko) * 2012-05-29 2014-06-27 한화케미칼 주식회사 항체 발현용 바이시스트로닉 발현벡터 및 이를 이용한 항체의 생산 방법

Also Published As

Publication number Publication date
EP3455359B1 (en) 2022-03-09
CN115873904A (zh) 2023-03-31
CN109219660B (zh) 2023-01-06
EP3455359A1 (en) 2019-03-20
US20230048658A1 (en) 2023-02-16
US20190127452A1 (en) 2019-05-02
MX2018013882A (es) 2019-03-14
AU2017263454A1 (en) 2018-12-06
IL262923B1 (en) 2023-04-01
AU2017263454B2 (en) 2023-02-09
IL300591A (en) 2023-04-01
JP6972022B2 (ja) 2021-11-24
EP4067493A1 (en) 2022-10-05
JP2019514417A (ja) 2019-06-06
EA201892588A1 (ru) 2019-06-28
AU2023200660A1 (en) 2023-03-09
ES2914118T3 (es) 2022-06-07
KR20190005193A (ko) 2019-01-15
TW201805422A (zh) 2018-02-16
BR112018073316A2 (pt) 2019-06-04
IL262923B2 (en) 2023-08-01
US11384140B2 (en) 2022-07-12
JP7344949B2 (ja) 2023-09-14
KR20210135635A (ko) 2021-11-15
MX2022009674A (es) 2022-09-09
CA3024027A1 (en) 2017-11-16
SG11201810040WA (en) 2018-12-28
CN109219660A (zh) 2019-01-15
TWI757291B (zh) 2022-03-11
WO2017197098A1 (en) 2017-11-16
MA44976A (fr) 2019-03-20
TWI821905B (zh) 2023-11-11
JP2022033734A (ja) 2022-03-02
IL262923A (en) 2019-01-31
KR102439719B1 (ko) 2022-09-02
TW202223093A (zh) 2022-06-16
KR102323519B1 (ko) 2021-11-09

Similar Documents

Publication Publication Date Title
CL2018003210A1 (es) Selección directa de células que expresan niveles altos de proteínas heterodiméricas usando vectores de complementación intragénica de glutamina sintetasa.
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
CO2017001573A2 (es) Receptor quimérico de antígeno anti-cd123
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
HK1250021A1 (zh) 用於肝臟中蛋白質表達的重組啟動子和載體及其用途
CO2017000510A2 (es) Constructos de car
CR20170139A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
BR112018001683A2 (pt) adenovírus recombinante, composição, uso de um adenovírus ou uma composição, e, adenovírus de símio não humano.
MD3583120T2 (ro) Polipeptide de legare la un receptor de transferină modificate
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
HRP20192173T8 (hr) Ekspresija rekombinantnih proteina u kukuljicama vrste trichoplusia ni
BR112017009262A2 (pt) métodos de produção de proteínas de duas cadeias em bactérias
EP4273233A3 (en) Mr1 restricted t cell receptors for cancer immunotherapy
MX2020012356A (es) Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes.
EA201791918A1 (ru) Модификация белков клеток-хозяев
PH12016501689A1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
SG11201912056WA (en) Fusion Protein With Half-Life Extending Polypeptide
DK3313864T3 (da) Rekombinante virusvektorer indeholdende prrsv minor protein og fremgangsmåder til fremstilling og anvendelse deraf
DK3277818T3 (da) Brug af vitaminer og vitaminstofskiftegener og -proteiner til produktion af rekombinant protein i pattedyrsceller
DK3218514T3 (da) Forudsigelse af genetisk stabil rekombinant proteinproduktion i tidlig cellelinieudvikling
MY178599A (en) Inducible pmt-gfpubx vector and its uses thereof
MY174846A (en) Inducible pmt-gfplabial vector and its uses thereof
AR089100A1 (es) Vectores basados en el virus citrus tristeza para la expresion de gene/s extraños